Patents Assigned to Rhone-Poulenc Rorer Pharmaceuticals Inc.
  • Treatment of conditions requiring enhanced oxygen availability of mammalian tissues
    Patent number: 5015663
    Abstract: Disclosed are pharmaceutical compositions containing naphthoic acid derivatives and method of use for enhancing oxygen availability to mammailian tissue.
    Type: Grant
    Filed: March 5, 1990
    Date of Patent: May 14, 1991
    Assignee: Rhone-Poulenc Rorer Pharmaceuticals Inc.
    Inventors: John T. Suh, Robert G. Pendleton, Charles E. Pendley, II, Kin T. Yu, Paul R. Menard, Alain B. Schreiber
  • Purification of von Willebrand Factor by affinity chromatography
    Patent number: 5006642
    Abstract: A method of preparing von Willebrand Factor by disassociating it from a chaotropic agent in solution therewith and preferably treating the same under controlled temperature either in liquid or lyophilized form.
    Type: Grant
    Filed: June 13, 1988
    Date of Patent: April 9, 1991
    Assignee: Rhone-Poulenc Rorer Pharmaceuticals Inc.
    Inventors: Jack Newman, David L. Farb
  • Compounds having cardiotonic activity
    Patent number: 5002944
    Abstract: Compounds useful for increasing cardiotonic contractility in humans or other animals and pharmaceutical compositions including these compounds are disclosed. The compounds have the general structure: ##STR1## where A is ##STR2## R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.9, and R.sub.10 are H, lower alkyl of 1-4 carbon atoms, phenyl, substituted phenyl, phenyl lower alkyl of 1-4 carbon atoms or substituted phenyl lower alkyl of 1-4 carbon atoms; and n is 0 or 1.
    Type: Grant
    Filed: May 11, 1989
    Date of Patent: March 26, 1991
    Assignee: Rhone-Poulenc Rorer Pharmaceuticals Inc.
    Inventors: Alfred P. Spada, Henry F. Campbell, Donald E. Kuhla, William L. Studt, William C. Faith, Bruce F. Molino
  • Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors
    Patent number: 5001144
    Abstract: Disclosed are novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors useful as antihypercholesterolemic agents represented by the formula ##STR1## and the corresponding ring-opened hydroxy acids derived therefrom and pharmaceutically acceptable salts thereof.Phamaceutical compositions containing said compounds and method of inhibiting the biosynthesis of cholesterol therewith are also disclosed.
    Type: Grant
    Filed: April 17, 1990
    Date of Patent: March 19, 1991
    Assignee: Rhone-Poulenc Rorer Pharmaceuticals Inc.
    Inventors: John R. Regan, Kent W. Neuenschwander
  • Des-17-histidine-calcitonin
    Patent number: 5001222
    Abstract: New peptides are disclosed which have biological activity of the same type as known calcitonins and which do not have a histidine in position 17. The position 17 histidine is omitted. Also resin peptides are disclosed which may be converted to peptides having such biological activity; and processes for producing said resin peptides and said calcitonin peptides.
    Type: Grant
    Filed: May 23, 1988
    Date of Patent: March 19, 1991
    Assignee: Rhone-Poulenc Rorer Pharmaceuticals Inc.
    Inventors: Ronald C. Orlowski, Robert L. Colescott
  • HMG-COA reductase inhibitors
    Patent number: 5001128
    Abstract: Disclosed are novel 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors useful as antihypercholesterolemic agents represented by the formula ##STR1## and the corresponding ring-opened hydroxy acids and esters derived therefrom and pharmaceutically acceptable salts thereof.Pharmaceutical compositions containing said compounds and method of inhibiting the biosynthesis of cholesterol therewith are also disclosed.
    Type: Grant
    Filed: December 15, 1989
    Date of Patent: March 19, 1991
    Assignee: Rhone-Poulenc Rorer Pharmaceuticals Inc.
    Inventors: Kent W. Neuenschwander, Anthony C. Scotese
  • HMG-CoA reductase inhibitors
    Patent number: 4996234
    Abstract: Disclosed are novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors useful as antihypercholesterolemic agents represented by the formula ##STR1## and the corresponding ring-opened hydroxy acids derived therefrom and pharmaceutically acceptable salts thereof.Pharmaceutical compositions containing said compounds and method of inhibiting the biosynthesis of cholesterol therewith are also disclosed.
    Type: Grant
    Filed: December 5, 1989
    Date of Patent: February 26, 1991
    Assignee: Rhone-Poulenc Rorer Pharmaceuticals Inc.
    Inventors: John R. Regan, Kent W. Neuenschwander
  • HMG-COA reductase inhibitors
    Patent number: 4994494
    Abstract: Disclosed are novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors useful as antihypercholesterolemic agents represented by the formula ##STR1## and the corresponding ring-opened hydroxy acids derived therefrom and pharmaceutically acceptable salts thereof.Pharmaceutical compositions containing said compounds and method of inhibiting the biosynthesis of cholesterol therewith are also disclosed.
    Type: Grant
    Filed: December 14, 1989
    Date of Patent: February 19, 1991
    Assignee: Rhone-Poulenc Rorer Pharmaceuticals Inc.
    Inventors: John R. Regan, Joseph G. Bruno, Kent W. Neuenschwander, Donald E. Kuhla
  • Novel HMG-COA reductase inhibitors
    Patent number: 4992429
    Abstract: Disclosed are novel substituted cyclohexenyl phosphinylhydroxybutyrates as 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors useful as antihypercholesterolemic agents represented by the formula: ##STR1## and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: August 24, 1989
    Date of Patent: February 12, 1991
    Assignee: Rhone-Poulenc Rorer Pharmaceuticals Inc.
    Inventors: John W. Ullrich, Kent W. Neuenschwander, John R. Regan